Niktimvo

News

Syndax shares fall as lung fibrosis drug fails trial

Syndax shares lost 17% of their value pre-market after the company said it abandoned development of axatilimab for idiopathic pulmonary fibrosis.

News

Incyte builds GvHD presence with Niktimvo approval

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder.

News

Flagship joins three biotechs together to form Etcelera

Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks